# US 2012/0083457 A1 · Bortezomib Formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083457 A1
- Document ID: US20120083457A1
- Status: Published application
- Kind: A1
- Application number: 13/252,421
- Filed: 2011-10-04
- Published: 2012-04-05
- Earliest claimed: 2010-10-05
- Assignees: APP Pharmaceuticals, LLC.
- Inventors: Arunya Usayapant; David Bowman
- Web page: https://patentgrep.com/patent/US20120083457A1

## CPC

- A61K 31/69: Boron compounds
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 33/22: Boron compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture.

## Claims

### Claim 1

A composition, comprising:
bortezomib, and
boric acid;
where the composition is a solid, and
the mass ratio of boric acid to bortezomib is from 1:1 to 10:1.

### Claim 2 (depends on 1)

The composition of claim 1, where the mass ratio of boric acid to bortezomib is from 1:1 to 4:1.

### Claim 3 (depends on 1)

The composition of claim 1, where the mass ratio of boric acid to bortezomib is from 2:1 to 3:1.

### Claim 4 (depends on 1)

The composition of claim 1, further comprising at least one other substance selected from the group consisting of an amino acid and a saccharide.

### Claim 5 (depends on 1)

The composition of claim 1, further comprising glycine,
where the mass ratio of glycine to bortezomib is from 1:1 to 20:1.

### Claim 6 (depends on 5)

The composition of claim 5, where the mass ratio of glycine to bortezomib is from 5:1 to 15:1.

### Claim 7 (depends on 5)

The composition of claim 5, where the mass ratio of glycine to bortezomib is from 7:1 to 10:1.

### Claim 8 (depends on 5)

The composition of claim 5, where
the mass ratio of boric acid to bortezomib is about 3:1, and
the mass ratio of glycine to bortezomib is about 7:1.

### Claim 9 (depends on 8)

The composition of claim 8, comprising about 3.5 mg bortezomib, about 10.5 mg boric acid, and about 25 mg glycine.

### Claim 10 (depends on 1)

The composition of claim 1, further comprising mannitol,
where the mass ratio of mannitol to bortezomib is from 1:1 to 20:1.

### Claim 11 (depends on 1)

The composition of claim 1, where at least a portion of the bortezomib is present in an anhydride structure.

### Claim 12 (depends on 1)

The composition of claim 1, where at least a portion of the bortezomib and boric acid are present together in an anhydride structure.

### Claim 13 (depends on 1)

The composition of claim 1, where when the composition is stored at 55° C., at most 5% of the bortezomib degrades after 3 weeks.

### Claim 14 (depends on 1)

The composition of claim 1, where when the composition is stored at 55° C., at most 2% of the bortezomib degrades after 3 weeks.

### Claim 15 (depends on 1)

The composition of claim 1, where when the composition is stored at 55° C., at most 1% of the bortezomib degrades after 3 weeks.

### Claim 16 (depends on 1)

The composition of claim 1, where when the composition is stored at 55° C., at most 0.5% of the bortezomib degrades after 3 weeks.

### Claim 17 (depends on 1)

The composition of claim 1, where
when the composition is combined with a 0.9% NaCl saline solution at a bortezomib concentration of 1 mg/mL saline and manually shaken every 15 seconds,
the composition forms a solution or an emulsion within 4 minutes.

### Claim 18 (depends on 17)

The composition of claim 17, where the composition forms the solution or the emulsion within 3 minutes.

### Claim at position 19

19-20. (canceled)

### Claim 21

A method of making a solid composition, comprising:
forming a liquid mixture comprising a solvent, bortezomib and boric acid, and
lyophilizing the liquid mixture.

### Claim at position 21

22-30. (canceled)

### Claim 31

A composition, formed by a method comprising:
forming a liquid mixture comprising a solvent, bortezomib and boric acid,
where the mass ratio of boric acid to bortezomib in the liquid mixture is from 1:1 to 10:1, and
lyophilizing the liquid mixture to form a solid composition.

### Claim at position 23

32-45. (canceled)
